Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hurley, Donald P
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen	Active, not recruiting	2	285	US	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	01/25	02/25
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain	Recruiting	2	384	US	RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo	Reata, a wholly owned subsidiary of Biogen	Diabetic Peripheral Neuropathic Pain	08/26	08/26
VALOR, NCT05953090: Vaginal Atrophy & Long-term Observation of Recovery	Recruiting	N/A	2000	US	7-0940, StrataMGT	Stratpharma AG	Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)	06/26	12/26
Cohen-Stein, Debbie
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension	Enrolling by invitation	3	1400	Europe, Canada, US, RoW	lorundrostat, Placebo	Mineralys Therapeutics Inc.	Hypertension	12/25	12/26
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen	Active, not recruiting	2	285	US	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	01/25	02/25